Cadila receives audit closure report

MUMBAI: Ahmedabad based Zydus Cadila’s on Wednesday said that the company has received an establishment inspection report (EIR) from the USFDA, that signifies a successful closure of the audit for its Moraiya facility.

The Moraiya manufacturing plant had completed the USFDA audit from February 6th to 15th 2017 with Zero 483 observations, the company said. Post the audit, the plant has received several product approvals, including the final approval to market the anti inflammatory drug Mesalamine tablets in the US.

Shares of Cadila remained neutral to the development.